Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: Infliximab as proof of principle

BACKGROUND: The development of anti-drug antibodies (ADA) in patients treated with therapeutic proteins can result in treatment failure. The clinically most relevant fraction of these antibodies are the neutralizing anti-drug antibodies (NAb) that block the pharmacological function of the drug. Cons...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Transl Autoimmun
Главные авторы: El Amrani, Mohsin, Göbel, Camiel, Egas, Annelies C., Nierkens, Stefan, Hack, C. Erik, Huitema, Alwin D.R., van Maarseveen, Erik M.
Формат: Artigo
Язык:Inglês
Опубликовано: Elsevier 2019
Предметы:
Research paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7388346/
https://ncbi.nlm.nih.gov/pubmed/32743494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtauto.2019.100004
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы